CV 8102

Drug Profile

CV 8102

Alternative Names: CV8102

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CureVac
  • Class Adjuvants; RNA; RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Head and neck cancer; Malignant melanoma; Rabies; Squamous cell cancer

Most Recent Events

  • 28 Sep 2017 CureVac plans a phase I trial for Malignant melanoma, Squamous cell cancer, Head and neck cancer (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) in Germany (Intratumoural) (NCT03291002)
  • 01 Sep 2017 Phase-I clinical trials in Squamous cell cancer, Malignant melanoma, Head and Neck cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in Germany (Intratumoural) (NCT03291002)
  • 01 Sep 2017 Phase-I clinical trials in Squamous cell cancer, Malignant melanoma, Head and neck cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in Germany (Intratumoural) (NCT03291002)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top